Open an account

Champions Oncology

CSBR · NASDAQ

$4.81+$0.12 (+2.56%)TodayMarket closed ·
Prev close $4.69

About CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

Employees
213
Headquarters
Hackensack, New Jersey
Listed
Nov 30, 1988
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
championsoncology.com

CSBR key statistics

Market cap
66.95M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.76K
Volume
1.77K
Open price
$4.71
High today
$4.82
Low today
$4.69
52 Week high
$8.31
52 Week low
$4.59

Champions Oncology (CSBR) at a glance

As of Oct 20, 2026, Champions Oncology (CSBR) shares are priced at $4.81, giving the company a market cap of 66.95M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.69 and $4.82. The current price is 2.6% above the day's low and 0.2% below its high.

Volume so far is 1.77K shares, below the average of 9.76K shares a day.

Over the past year Champions Oncology has ranged from $4.59 to $8.31, and now sits 6% of the way up that range.

Champions Oncology met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q1 FY27 it reported -$0.03 per share against an estimate of -$0.0102.

CSBR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 746.6% on average.

  1. Q2 FY25: reported $0.05 per share against an estimate of $0.0102
  2. Q3 FY25: reported $0.36 per share against an estimate of -$0.0102
  3. Q4 FY25: reported -$0.07 per share against an estimate of -$0.204
  4. Q1 FY26: reported $0.02 per share against an estimate of -$0.0102
  5. Q2 FY26: reported $0.02 per share against an estimate of $0.0102
  6. Q3 FY26: reported -$0.02 per share against an estimate of $0.0918
  7. Q4 FY26: reported -$0.05 per share against an estimate of -$0.051
  8. Q1 FY27: reported -$0.03 per share against an estimate of -$0.0102

CSBR news

  • Vishaal Sanjay

    4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

  • Market-Moving News for September 12th

  • A Preview Of Champions Oncology's Earnings

Similar companies

Companies in the same industry as Champions Oncology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.